title: Montelukast, a cysteinyl leukotriene receptor-1 antagonist, attenuates chronic brain injury after focal cerebral ischaemia in mice and rats.
abstract: OBJECTIVE
  Previously we demonstrated the neuroprotective effect of montelukast, a cysteinyl leukotriene receptor-1 (CysLT(1) ) antagonist, on acute brain injury after focal cerebral ischaemia in mice. In this study, we have determined its effect on chronic brain injury after focal cerebral ischaemia in mice and rats.
  
  
  METHODS
  After transient focal cerebral ischaemia was induced by middle cerebral artery occlusion, montelukast was intraperitoneally injected in mice or orally administered to rats for five days. Behavioural dysfunction, brain infarct volume, brain atrophy and neuron loss were determined to evaluate brain lesions.
  
  
  RESULTS
  Montelukast (0.1 mg/kg) attenuated behavioural dysfunction, brain infarct volume, brain atrophy and neuron loss in mice, which was similar to pranlukast, another CysLT(1) receptor antagonist. Oral montelukast (0.5 mg/kg) was effective in rats and was more effective than edaravone, a free radical scavenger.
  
  
  CONCLUSIONS
  Montelukast protected mice and rats against chronic brain injury after focal cerebral ischaemia, supporting the therapeutic potential of CysLT(1) receptor antagonists.
authors.affiliation: Department of Pharmacology, School of Medicine, Zhejiang University Department of Pharmacy, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou Department of Physiology and Department of Neurobiology, Xuzhou Medical College, Xuzhou, Jiangsu, China.
authors.forename: Rui
authors.initials: R
authors.lastname: Zhao
authors.forename: Wen-Zhen
authors.initials: WZ
authors.lastname: Shi
authors.forename: Yong-Mei
authors.initials: YM
authors.lastname: Zhang
authors.forename: San-Hua
authors.initials: SH
authors.lastname: Fang
authors.forename: Er-Qing
authors.initials: EQ
authors.lastname: Wei
mesh_terms: D000085:Acetates / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D000284:Administration, Oral; D000818:Animals; D000983:Antipyrine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D001284:Atrophy / Q000517:prevention & control; D001522:Behavior, Animal / Q000187:drug effects; D020208:Brain Injury, Chronic / Q000150:complications / Q000473:pathology* / Q000517:prevention & control*; D002867:Chromones / Q000627:therapeutic use; D003521:Cyclopropanes; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical; D000077553:Edaravone; D016166:Free Radical Scavengers / Q000627:therapeutic use; D020244:Infarction, Middle Cerebral Artery / Q000188:drug therapy* / Q000473:pathology*; D007274:Injections, Intraperitoneal; D020024:Leukotriene Antagonists / Q000494:pharmacology / Q000627:therapeutic use; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D009410:Nerve Degeneration / Q000188:drug therapy*; D011804:Quinolines / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013440:Sulfides
chemical_list: D000085:Acetates; D002867:Chromones; D003521:Cyclopropanes; D016166:Free Radical Scavengers; D020024:Leukotriene Antagonists; D011804:Quinolines; D013440:Sulfides; C093875:montelukast; D000077553:Edaravone; D000983:Antipyrine; C047681:pranlukast